Charles D - Search Results

1

Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.

Hassell TJW, Charles D. Hassell TJW, et al. Among authors: charles d. Toxins (Basel). 2020 Apr 22;12(4):269. doi: 10.3390/toxins12040269. Toxins (Basel). 2020. PMID: 32331272 Free PMC article. Review.

2

Continuation of long-term care for cervical dystonia at an academic movement disorders clinic.

Gill CE, Manus ND, Pelster MW, Cook JA, Title W, Molinari AL, Charles D. Gill CE, et al. Among authors: charles d. Toxins (Basel). 2013 Apr 23;5(4):776-83. doi: 10.3390/toxins5040776. Toxins (Basel). 2013. PMID: 23612751 Free PMC article.

3

INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.

Misra VP, Colosimo C, Charles D, Chung TM, Maisonobe P, Om S; INTEREST IN CD2 study group. Misra VP, et al. Among authors: charles d. J Neurol. 2018 Feb;265(2):402-409. doi: 10.1007/s00415-017-8698-2. Epub 2017 Dec 21. J Neurol. 2018. PMID: 29270685 Free PMC article.

4

How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.

Colosimo C, Charles D, Misra VP, Maisonobe P, Om S; INTEREST IN CD2 study group. Colosimo C, et al. Among authors: charles d. J Neurol. 2019 Dec;266(12):3038-3046. doi: 10.1007/s00415-019-09527-2. Epub 2019 Sep 9. J Neurol. 2019. PMID: 31501975 Free PMC article.

5

Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.

Colosimo C, Charles D, Misra VP, Maisonobe P, Om S; INTEREST IN CD2 study group. Colosimo C, et al. Among authors: charles d. J Neurol Sci. 2020 Sep 15;416:117015. doi: 10.1016/j.jns.2020.117015. Epub 2020 Jul 9. J Neurol Sci. 2020. PMID: 32682125 Free article.

6

Combined treatment with BTX-A and ITB for spasticity: case report.

Gill CE, Andrade EO, Blair CR, Taylor HM, Charles D. Gill CE, et al. Among authors: charles d. Tenn Med. 2007 Oct;100(10):41-2, 44. Tenn Med. 2007. PMID: 17966716

7

Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.

Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF; CD 140 Study Group. Charles D, et al. Clin Neuropharmacol. 2012 Sep-Oct;35(5):208-14. doi: 10.1097/WNF.0b013e31826538c7. Clin Neuropharmacol. 2012. PMID: 22948497 Clinical Trial.

8

Botulinum toxin injection techniques for the management of adult spasticity.

Walker HW, Lee MY, Bahroo LB, Hedera P, Charles D. Walker HW, et al. Among authors: charles d. PM R. 2015 Apr;7(4):417-27. doi: 10.1016/j.pmrj.2014.09.021. Epub 2014 Oct 8. PM R. 2015. PMID: 25305369 Review.

9

Correction to: How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.

Colosimo C, Charles D, Misra VP, Maisonobe P, Om S; INTEREST IN CD2 study group. Colosimo C, et al. Among authors: charles d. J Neurol. 2019 Dec;266(12):3047. doi: 10.1007/s00415-019-09549-w. J Neurol. 2019. PMID: 31595379 Free PMC article.

10

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.

Comella C, Hauser RA, Isaacson SH, Truong D, Oguh O, Hui J, Molho ES, Brodsky M, Furr-Stimming E, Comes G, Hast MA, Charles D. Comella C, et al. Among authors: charles d. Clin Park Relat Disord. 2022 Mar 14;6:100142. doi: 10.1016/j.prdoa.2022.100142. eCollection 2022. Clin Park Relat Disord. 2022. PMID: 35330880 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

519 results

Search Page